Unveiling the Future of Cancer Treatment: Glycotope Showcases Breakthrough Glyco-Engineered Cell Lines at AACR 2023

Glycotope GmbH, a biotechnology company utilizing an innovative platform technology to develop antibodies against proteins carrying tumor-specific carbohydrate structures, will present its glyco-engineered cell lines at the 2022 American Association for Cancer Research (AACR) Meeting in Orlando, Florida from 14-19 April 2023.

This cutting-edge technology promises to revolutionize the way we treat cancer, providing a more targeted and effective approach to combat this devastating disease.

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH, is thrilled to present their groundbreaking glyco-engineered cell lines at the 2023 AACR Annual Meeting. These cell lines provide the basis for a new generation of therapeutic antibodies with increased tumor specificity and safety for highly potent therapeutic approaches like ADCs, CARs and radiotherapeutics.

Glycotope’s proprietary platform offers a versatile tool for target validation and screening of glycosylation-dependent protein binding antibodies, making it a valuable resource for cancer research experts.

About Glycotope

Glycotope is revolutionizing cancer treatment with its proprietary technology platform, which enables the development of monoclonal antibodies that specifically target tumor-associated carbohydrate structures and protein/carbohydrate combined glyco-epitopes (GlycoTargets).

To date, our groundbreaking approach has uncovered more than 200 GlycoTargets, and our antibodies against several of these targets are currently in development, paving the way for more effective and personalized cancer therapies.

Our antibodies offer unparalleled tumor-specificity, making them the perfect choice for a range of innovative treatments, including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies, and fusion-proteins. Unlock the potential of these cutting-edge therapies and take your treatments to the next level.

Leave a Comment